RxDoctor Payments Data

Ricardo Mendoza, MD

Cytopathology · Dover, DENPI 1417104936

Payments from drug & device makers

$730in general payments, 2019–2025

Across 20 payments — averaging $36.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$144
  • Exelixis Inc.$118
  • Corcept Therapeutics$96
  • Insulet Corporation$87
  • Boehringer Ingelheim$72
  • Lilly USA, LLC$50
  • plus $162 from 7 others

What the payments were for

  • Food & beverage$730100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cytopathology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$152,761
Medicare patients
391
Services billed
1,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Where these figures come from

Is this you, or does something look wrong? →